Modality
mRNA
MOA
CD3xCD20
Target
KIF18A
Pathway
PI3K/AKT
CTCL
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Jan 2025
Phase 1Current
NCT03777620
501 pts·CTCL
2021-05→2025-01·Terminated
501 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-041.2y agoInterim· CTCL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P1
Termina…
Catalysts
Interim
2025-01-04 · 1.2y ago
CTCL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03777620 | Phase 1 | CTCL | Terminated | 501 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D |